These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 20522011)

  • 21. PPAR-δ is repressed in Huntington's disease, is required for normal neuronal function and can be targeted therapeutically.
    Dickey AS; Pineda VV; Tsunemi T; Liu PP; Miranda HC; Gilmore-Hall SK; Lomas N; Sampat KR; Buttgereit A; Torres MJ; Flores AL; Arreola M; Arbez N; Akimov SS; Gaasterland T; Lazarowski ER; Ross CA; Yeo GW; Sopher BL; Magnuson GK; Pinkerton AB; Masliah E; La Spada AR
    Nat Med; 2016 Jan; 22(1):37-45. PubMed ID: 26642438
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic mouse models of Huntington's disease: focus on electrophysiological mechanisms.
    Cepeda C; Cummings DM; André VM; Holley SM; Levine MS
    ASN Neuro; 2010 Apr; 2(2):e00033. PubMed ID: 20396376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dysfunctional Dopaminergic Neurones in Mouse Models of Huntington's Disease: A Role for SK3 Channels.
    Dallérac GM; Levasseur G; Vatsavayai SC; Milnerwood AJ; Cummings DM; Kraev I; Huetz C; Evans KA; Walters SW; Rezaie P; Cho Y; Hirst MC; Murphy KP
    Neurodegener Dis; 2015; 15(2):93-108. PubMed ID: 25871323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Huntington's disease: clinical and molecular genetics].
    Warita H; Shiro Y; Kashihara K; Abe K
    Nihon Rinsho; 1999 Apr; 57(4):896-9. PubMed ID: 10222786
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chapter 33: the history of movement disorders.
    Lanska DJ
    Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutant huntingtin can paradoxically protect neurons from death.
    Zuchner T; Brundin P
    Cell Death Differ; 2008 Mar; 15(3):435-42. PubMed ID: 17975550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Weight loss in Huntington disease increases with higher CAG repeat number.
    Aziz NA; van der Burg JM; Landwehrmeyer GB; Brundin P; Stijnen T; ; Roos RA
    Neurology; 2008 Nov; 71(19):1506-13. PubMed ID: 18981372
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent insights into the molecular pathogenesis of Huntington disease.
    Leavitt BR; Wellington CL; Hayden MR
    Semin Neurol; 1999; 19(4):385-95. PubMed ID: 10716661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In Vivo Multidimensional Brain Imaging in Huntington's Disease Animal Models.
    Flament J; Hantraye P; Valette J
    Methods Mol Biol; 2018; 1780():285-301. PubMed ID: 29856025
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].
    Hattori N
    Rinsho Shinkeigaku; 2004; 44(4-5):241-62. PubMed ID: 15287506
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective reduction of striatal mature BDNF without induction of proBDNF in the zQ175 mouse model of Huntington's disease.
    Ma Q; Yang J; Li T; Milner TA; Hempstead BL
    Neurobiol Dis; 2015 Oct; 82():466-477. PubMed ID: 26282324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Experimental models of HD and reflection on therapeutic strategies.
    Kim J; Bordiuk OL; Ferrante RJ
    Int Rev Neurobiol; 2011; 98():419-81. PubMed ID: 21907096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Murine Models of Huntington's Disease for Evaluating Therapeutics.
    Kosior N; Leavitt BR
    Methods Mol Biol; 2018; 1780():179-207. PubMed ID: 29856020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early white matter abnormalities, progressive brain pathology and motor deficits in a novel knock-in mouse model of Huntington's disease.
    Jin J; Peng Q; Hou Z; Jiang M; Wang X; Langseth AJ; Tao M; Barker PB; Mori S; Bergles DE; Ross CA; Detloff PJ; Zhang J; Duan W
    Hum Mol Genet; 2015 May; 24(9):2508-27. PubMed ID: 25609071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Global changes to the ubiquitin system in Huntington's disease.
    Bennett EJ; Shaler TA; Woodman B; Ryu KY; Zaitseva TS; Becker CH; Bates GP; Schulman H; Kopito RR
    Nature; 2007 Aug; 448(7154):704-8. PubMed ID: 17687326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitigation of augmented extrasynaptic NMDAR signaling and apoptosis in cortico-striatal co-cultures from Huntington's disease mice.
    Milnerwood AJ; Kaufman AM; Sepers MD; Gladding CM; Zhang L; Wang L; Fan J; Coquinco A; Qiao JY; Lee H; Wang YT; Cynader M; Raymond LA
    Neurobiol Dis; 2012 Oct; 48(1):40-51. PubMed ID: 22668780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cholinergic neuronal defect without cell loss in Huntington's disease.
    Smith R; Chung H; Rundquist S; Maat-Schieman ML; Colgan L; Englund E; Liu YJ; Roos RA; Faull RL; Brundin P; Li JY
    Hum Mol Genet; 2006 Nov; 15(21):3119-31. PubMed ID: 16987871
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein aggregation in Huntington's and Parkinson's disease: implications for therapy.
    Wanker EE
    Mol Med Today; 2000 Oct; 6(10):387-91. PubMed ID: 11006527
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease.
    Sebastianutto I; Cenci MA; Fieblinger T
    Neurobiol Dis; 2017 Sep; 105():117-131. PubMed ID: 28578004
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.